Management may also involve correcting biochemical abnormalities associated with CKD–MBD by lowering phosphate levels, reducing calcium intake, and/or using calcimimetics such as cinacalcet, which increases the sensitivity of the calcium-sensing receptor (CaSR) and reduces PTH secretion. This evidence concerns the gene CASR and chronic kidney disease.